Fate Therapeutics Stock Beneish M Score
| FATE Stock | USD 2.07 0.15 6.76% |
Fate | Beneish M Score |
At this time, it appears that Fate Therapeutics is an unlikely manipulator. The earnings manipulation may begin if Fate Therapeutics' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Fate Therapeutics executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Fate Therapeutics' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-2.78
Beneish M Score - Unlikely Manipulator
Fate Therapeutics Beneish M-Score Indicator Trends
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Fate Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Net Receivables | 1.7 M | 1.8 M |
|
| |||||
| Total Assets | 310.1 M | 506.2 M |
|
| |||||
| Total Current Assets | 234.9 M | 331.5 M |
|
| |||||
| Non Current Assets Total | 183.4 M | 174.7 M |
|
| |||||
| Property Plant Equipment | 212.6 M | 202.5 M |
|
| |||||
| Depreciation And Amortization | 19.2 M | 18.3 M |
|
| |||||
| Selling General Administrative | 85.5 M | 81.4 M |
|
| |||||
| Total Current Liabilities | 36.6 M | 39.1 M |
|
| |||||
| Non Current Liabilities Total | 63.3 M | 98.7 M |
|
| |||||
| Short Term Debt | 6.4 M | 12.4 M |
|
|
Fate Therapeutics Beneish M-Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Fate Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Fate Therapeutics in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Fate Therapeutics' degree of accounting gimmicks and manipulations.
Click cells to compare fundamentals
About Fate Therapeutics Beneish M Score
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Depreciation And Amortization |
|
Fate Therapeutics Earnings Manipulation Drivers
Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Fate Therapeutics. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Receivables | 1.3M | 5.5M | 8.7M | 38.5M | 1.8M | 1.7M | |
| Total Revenue | 10.7M | 31.4M | 55.8M | 96.3M | 63.5M | 66.7M | |
| Total Assets | 302.3M | 622.5M | 921.5M | 705.6M | 506.2M | 310.1M | |
| Total Current Assets | 227.1M | 494.3M | 633.4M | 502.1M | 331.5M | 234.9M | |
| Net Debt | (72.9M) | (70.0M) | (18.8M) | 48.0M | 61.7M | 64.7M | |
| Short Term Debt | 1.7M | 6.7M | 11.2M | 11.3M | 12.4M | 6.4M | |
| Operating Income | (100.7M) | (128.1M) | (217.0M) | (308.4M) | (190.5M) | (181.0M) | |
| Investments | (150.1M) | (156.1M) | (273.3M) | 166.8M | 120.4M | 126.4M | |
| Gross Profit Margin | (7.22) | (3.0) | 0.9 | 0.86 | (1.55) | (1.62) |
Fate Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Fate Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Fate Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
About Fate Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fate Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fate Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fate Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Fate Therapeutics is a strong investment it is important to analyze Fate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Fate Therapeutics' future performance. For an informed investment choice regarding Fate Stock, refer to the following important reports:Check out Fate Therapeutics Piotroski F Score and Fate Therapeutics Altman Z Score analysis. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share 0.123 | Quarterly Revenue Growth 0.581 | Return On Assets (0.22) | Return On Equity (0.47) |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.